Magellan Health (NASDAQ:MGLN) issued an update on its FY19 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of $3.70-4.69 for the period, compared to the Thomson Reuters consensus estimate of $4.50. The company issued revenue guidance of $7.2-7.5 billion, compared to the consensus revenue estimate of $7.11 billion.Magellan Health also updated its FY 2019 guidance to $3.70-4.69 EPS.
MGLN traded up $1.52 on Friday, reaching $57.01. The company had a trading volume of 6,999 shares, compared to its average volume of 375,676. The company has a market capitalization of $1.34 billion, a P/E ratio of 10.36, a P/E/G ratio of 1.53 and a beta of 0.47. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.72 and a quick ratio of 1.67. Magellan Health has a 52-week low of $51.88 and a 52-week high of $112.25.
Magellan Health (NASDAQ:MGLN) last announced its earnings results on Wednesday, November 7th. The company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.28. The business had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.85 billion. Magellan Health had a net margin of 1.49% and a return on equity of 10.93%. Magellan Health’s quarterly revenue was up 30.6% on a year-over-year basis. During the same period last year, the firm posted $1.64 earnings per share. On average, equities analysts anticipate that Magellan Health will post 3.61 earnings per share for the current year.
MGLN has been the topic of a number of recent analyst reports. TheStreet downgraded shares of Magellan Health from a b- rating to a c+ rating in a research note on Friday, November 9th. ValuEngine raised shares of Magellan Health from a strong sell rating to a sell rating in a research note on Wednesday, November 28th. Zacks Investment Research downgraded shares of Magellan Health from a hold rating to a sell rating in a research note on Saturday, October 13th. Leerink Swann downgraded shares of Magellan Health from an outperform rating to a market perform rating and lowered their target price for the company from $90.00 to $70.00 in a research note on Tuesday, November 13th. Finally, BidaskClub downgraded shares of Magellan Health from a strong-buy rating to a buy rating in a research note on Friday, August 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $83.33.
ILLEGAL ACTIVITY WARNING: This article was reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://transcriptdaily.com/2018/12/07/magellan-health-mgln-releases-fy19-earnings-guidance.html.
About Magellan Health
Magellan Health, Inc provides healthcare management services in the United States. It operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine for health plans, care organizations, and employers.
Featured Article: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with MarketBeat.com's FREE daily email newsletter.